Table A2.
Clinical and Pathologic Features of the Patients in the Model Building Case-Control Study Using Formalin-Fixed, Paraffin-Embedded Tissues
| Feature | Case (n = 76)
|
Control (n = 81)
|
P | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age at surgery | .24 | ||||
| Mean | 65.3 | 64.0 | |||
| Standard deviation | 6.8 | 6.8 | |||
| Median | 67 | 65 | |||
| Range | 47.0-78.0 | 48.0-77.0 | |||
| Preoperative PSA, ng/mL | .97 | ||||
| Median | 10.1 | 12.0 | |||
| Q1 | 6.1 | 6.9 | |||
| Q3 | 23.1 | 24.6 | |||
| Range | 1.3-143.0 | 1.7-119.0 | |||
| Gleason score | .35 | ||||
| 7 | 43 | 56.6 | 42 | 51.9 | |
| 8+ | 33 | 43.4 | 39 | 48.1 | |
| Pathologic stage, 1997 TNM | .23 | ||||
| T2aN0 | 8 | 10.5 | 9 | 11.1 | |
| T2bN0 | 11 | 14.4 | 18 | 22.2 | |
| T34N0 | 44 | 57.9 | 38 | 46.9 | |
| TxN+ | 13 | 17.1 | 16 | 19.7 | |
| Margin positive | 51 | 67.1 | 50 | 61.7 | .27 |
| Ploidy | < .001 | ||||
| Diploid | 26 | 34.2 | 42 | 51.9 | |
| Tetraploid | 31 | 40.8 | 33 | 40.7 | |
| Aneuploid | 19 | 25.0 | 6 | 7.4 | |
| Adjuvant treatment | |||||
| Hormone | 27 | 35.5 | 27 | 33.3 | .77 |
| Radiation | 11 | 14.5 | 12 | 14.8 | .95 |
Abbreviations: PSA, prostate-specific antigen; Q1, 25th percentile; Q3, 75th percentile.